Prenatal exposure to perfluorooctanoic acid and childhood allergic
diseases: a prospective birth cohort study
Abstract
Background Perfluorooctanoic acid (PFOA) is widely used in
daily life, however, research has shown its immune suppression function.
Our aim is to investigate the relationship between prenatal exposure to
PFOA and allergic diseases in children. Methods A prospective
birth cohort study involving 648 pregnant women was conducted. Prenatal
information was collected by an interview with the women and from
medical records. Fetal umbilical cord blood was collected, and
concentration of PFOA and genotype of IL-13 rs20541 were detected.
Children were followed at 6, 12 and 24 months and information on the
development of allergic diseases was recorded. Multivariate logistic
regression analysis was used to examine the association between PFOA and
allergic diseases. Stratified analysis was performed based on gender and
genotype of IL-13 rs20541. Results In multivariate adjusted
models, the highest PFOA quartile is associated with odds of atopic
dermatitis (AD) (OR 1.66, 95% CI 1.09-2.55), wheezing (OR 4.06, 95% CI
1.30-12.68), and allergic diseases (OR 1.71, 95% CI 1.15-2.54). Female
patients with the highest PFOA quartile have a higher odd of AD (OR
2.25, 95% CI 1.20-4.23) and allergic diseases (OR 1.93, 95% CI
1.07-3.46). Patients with GG genotype of IL-13 rs20541 and the highest
PFOA quartile also have a higher odd of AD (OR 2.82, 95% CI 1.41-5.67),
wheezing (OR 15.16, 95% CI 1.38-166.59), and allergic diseases (OR
2.42, 95% CI 1.27-4.61). Conclusions Prenatal exposure to PFOA
increases the risk of developing allergic diseases in children,
especially for the female patients and those with the genotype of IL-13
rs20541 GG.